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I. Abstract
The plasmid p1471 was isolated from the ciprofloxacin (Cp) resistant Aeromonas hydrophila, medicinal
leech isolate JG1471, which is a strain with a minimum inhibitory concentration (MIC) of > 32 µg/mL Cp.
JG1471 carries a 6.8 Kb plasmid which contains Cp resistance gene qnrS2. qnrS2 is a plasmid mediated
resistance gene that has been isolated from clinical and environmental sources and has been implicated
in increased resistance to the fluoroquinolone (FQ) Cp. To determine the FQ resistance conferred by
qnrS2, primers were designed to perform a Gibson Assembly to insert a 1.99 Kb fragment from pKAS46,
containing an Escherichia coli origin of replication (R6K), multiple cloning sites (MCS) and a kanamycin
(Km) resistance gene into the 6.8 Kb p1471. The R6K origin of replication allows successful plasmid
replication in E. coli, while the Km resistance factors allow for selection of both Aeromonas and E. coli
strains containing the construct. The presence of the MCS in the construct makes it possible for the
plasmid to be used as a shuttle vector in future experiments. The assembled construct, pEL1, was
transformed into the E. coli DH5α-λ pir strain. Several assays were then performed to confirm that the
plasmid construct was assembled correctly. E. coli showed a marked increase in ciprofloxacin resistance
upon addition of pEL1, with a ~8-fold increase in MIC from 0. 032 µg/mL to 0.25 µg/mL. When pEL1 was
transformed into a CpS strain of Aeromonas veronii, the MIC showed a 3,000-fold increase, from 0.002
µg/mL to 6 µg/mL, passing the 4 µg/mL clinical benchmark for resistance. This data suggests that the
presence of qnrS2 in p1471, a high copy plasmid, may play a substantial role in the CpR of the strain.
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II. Introduction
Leeches have been used as medicinal tools since 200 BCE, though substantial changes have
occurred in their prescribed use1. The European medicinal leech, Hirudo verbana, is no longer used to
remove ‘evil spirits’ as it was in medieval times2. Instead, leech therapy employing H. verbana leeches is
now a commonly used procedure for a broad spectrum of purposes that include application after
reconstructive and plastic surgery such as digit replantation and graft transplants2. Leeches for
hirudotherapy are purchased from Leeches USA, which is the only FDA-approved supplier of the
medicinal leech for hirudotherapy. During and after hirudotherapy, venous congestion in the
transplanted or reconstructed tissue wound site can present a real challenge to attaining successful
outcome of the surgery. Venous blood return from the wound site dramatically decreases due to blood
clotting and disruption of veins3. Leeches secrete vasodilators and anticoagulants like hirudin, which
allow for improved blood flow to the surgically reconstructed sites and inhibit the activity of thrombin,
an enzyme with critical roles in coagulation of blood4. Several other proteins secreted by the leech allow
for increased blood flow to the area and increased prevention of blood clotting so that venous
congestion does not occur and the surgical area can continue to receive enough blood flow to eventually
heal4. When post-operative venous congestion was observed in digit replantation performed by Dr.
Tamai, he reported 17% salvage rate without any use of leeches5. When Dr. Iain Whitaker studied digit
replantation with use of leeches, he observed a 70% salvage of the tissues6. A 77.98% salvage rate was
observed as a result of leech therapy after reconstructive surgery in 277 cases overall3. Since physicians
have begun to use hirudotherapy, tissue salvage has been substantially improved3.
While hirudotherapy is well established as a tool for tissue salvage in reconstructive surgery, this
procedure is not without its risks; one consequence of hirudotherapy is an increased risk of infection. In
some cases, infection as a result of leech therapy can lead to cellulitis, a simple bacterial infection of the
skin. In more extreme cases, tissue loss and septicemia can occur as a result of infection, leading to
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failure of the reconstruction or even death7. Without prophylactic antibiotic treatment, Whitaker
observed a 26% infection rate of the reconstructed tissue after hirudotherapy. Upon addition of
prophylactic treatment with antibiotics, however, Whitaker observed that the infection rate can go from
26% to 12.5% of patients6. With the decreased infection rate comes an increased success rate of the
surgical reconstruction6.
Infections following leech therapy are a result of the bacterial symbionts that reside in the gut of
the medicinal leech. H. verbana has two main bacterial symbionts: Aeromonas species and Mucinivorans
hirudinis,8. Aeromonas hydrophila is one of the Aeromonas species isolated from the gut of the leech,
and is the primary isolate published in case reports describing infection with leech therapy. A.
hydrophila is a member of the family Aeromonadaceae9. It is Gram-negative, rod shaped, motile, and a
facultative anaerobe9. M. hirudinis is an anaerobic bacteria of the family Rikenellaceae that was isolated
and cultivated on mucin-containing plates10.
Symbiosis is a close association between two biological partners. In the case of H. verbana, it has
been suggested that its symbionts provide the leech host with extra nutrients, such as acetate and B
vitamins that the host is unable to produce by itself11,12. It has also been hypothesized that the gut
symbionts play a role in prevention of pathogens in the blood meal from colonization of the gut of the
leech13. On the other hand, the leech host provides the symbionts with nutrients and an environment
for successful growth. Host-produced mucin is thought to allow Mucinivorans to proliferate8. Sialic acid
utilization genes in Aeromonads allow them to digest and utilize the sialic acid provided by the host14.
Certain genetic markers that allow Aeromonas to be pathogenic are utilized as colonization factors when
Aeromonas is present in the leech. For example, the normally pathogenic Type II secretion system (T2SS)
in Aeromonas species is necessary for colonization of the gut of the leech by the bacteria15. When the
T2SS was inactivated by transposon mutagenesis, the Aeromonas strain was initially unable to colonize
the gut of the leech15. The T2SS allows hemolysis of red blood cells in the blood meal, and when it is
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knocked out, the mutant is unable to colonize this niche15. While these bacteria are beneficial symbionts
in the leech gut, they can act as pathogens in other settings: the T2SS found in A. veronii has been
implicated in pathogenicity and Aeromonas hydrophila, in particular, is the bacteria most commonly
associated with wound infections following hirudotherapy15,7.
Standard procedure in clinical hirudotherapy includes prophylactic treatment with
fluoroquinolones (FQs) such as ciprofloxacin (Cp) to prevent infection of the wound with Aeromonas
species3. FQs are useful drugs when it comes to treatment of bacterial infections because they target
the process of replication, reducing the ability of the bacteria to survive16. FQ’s enter the bacterial cell by
passive diffusion (specifically through porins in the outer membrane in Gram-negative bacteria and
through the lipid bilayer)17. Once inside the cell, FQs bind to and inhibit the actions of topoisomerase
proteins such as DNA gyrase (made up of protein subunits gyrA and gyrB) and topoisomerase IV
(consisting of subunits parC and parE) which bind to the DNA to introduce supercoils that allow the DNA
to be unwound downstream and then remove negative supercoils from the DNA when ATP is no longer
present16. FQ’s prevent DNA replication by direct interference in the replication process, with
bactericidal effects on both Gram-negative and Gram-positive bacteria16. With the FQ bound to the
enzyme, the supercoiling process will not continue and DNA cannot be replicated16 In Gram-negative
bacteria, DNA gyrase is the primary FQ binding site, while topoisomerase IV is the main target in Grampositive bacteria18,16. In Gram-negative bacteria, FQ’s bind to DNA gyrase while it is bound to the DNA16.
In Gram-positive bacteria, FQs bind to DNA type IV topoisomerase and produce bactericidal effects by
binding to the DNA-topoisomerase complex while there is a break in the DNA, just as it does with DNA
gyrase, making FQs very useful antimicrobials16.
The enhanced bactericidal effects of the synthetic drug, Cp, against Gram-negative bacteria
make it the treatment of choice for Aeromonas infections resulting from hirudotherapy. While there are
multiple FQs on the market, Cp is meant for human use19. Hirudotherapy is not the only route for
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human acquisition of CpR bacterial infections. Resistance to enrofloxacin can also lead to CpR and human
illness. In 2005, pharmaceutical companies withdrew enrofloxacin from use in poultry farms in the
United States due to lack of FDA approval. Studies have shown that resistance to enrofloxacin developed
in chickens treated for widespread infection of Campylobacter species20. Reports of FQ resistant
Campylobacter bacteria associated with human consumption of infected poultry became more frequent.
The patients acquired the resistant bacteria and experienced infection that could not be treated with
clinically determined levels of ciprofloxacin21.
Infections due to CpR Aeromonas bacteria, however, did not occur until 2011. Before 2011,
prophylactic treatment of the patient with Cp was effective in prevention of infection. That year,
however, Cp-resistant strains of Aeromonas hydrophila were isolated from wound infections following
hirudotherapy, in some cases leading to tissue necrosis and loss of the reconstructed area22. When
patients experience wound infections following hirudotherapy, the salvage rate of their tissue is 37.4%,
while the tissue salvage rate is 88.3% when infection does not occur3. These statistics do not
differentiate between patients who experience prophylactic treatment with Cp and those who don’t,
but resistance to Cp, the commonly used prophylactic treatment, will likely continue to increase the rate
of infection and subsequent tissue failure following hirudotherapy3.
Cp resistance can be a result of several cellular changes. One of the first steps toward resistance
is a mutation in the gyrA or parC subunits of DNA gyrase and topoisomerase IV, the two targets of Cp’s
bactericidal mechanisms. When mutations occur in gyrA and parC, they primarily lead to amino acid
changes in the active sites of the enzyme18. With a single point mutation in the quinolone resistance
determining region (QRDR) of gyrA, resistance to ciprofloxacin can occur18. Bacteria with high-sensitivity
DNA gyrase or topoisomerase IV enzymes have lower minimum inhibitory concentrations (MIC) of FQ’s,
which is the concentration of antibacterial compound required to inhibit visible growth. These bacteria
with highly sensitive enzymes have much lower MIC values than those with more Cp resistance, so it is
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hypothesized that a mutation in both gyrA and parC that makes the replication enzymes less sensitive
would lead to an even higher MIC than a single point mutation in either region would provide18. FQ’s
can diffuse into the cell through porins, so downregulation or mutations in porin proteins can contribute
to resistance as well23. While chromosomal mutations and the resistance provided by the QRDR are
important factors in Cp resistance, Cp resistance can also be increased as a result of plasmid-mediated
resistance genes23.
Plasmid-mediated factors are commonly found in CpR bacteria. One example of a plasmidmediated resistance factor is an efflux pump, a transmembrane pump that actively transports
bactericidal compounds such as Cp out of the cell23. Genes encoding efflux pump proteins such as QepA
and OqxAB are also thought to factor into Cp resistance. QepA provided a 32-fold increase in MIC of Cp
when conjugated into E. coli23. QepA is a transmembrane protein that actively pumps out Cp from the
cell23. QepA is just one of several plasmid-mediated resistance mechanisms. Another mechanism
involves modification of Cp itself through a mutated aminoglycoside acetyl-transferase gene called
aac(60)-Ib-cr, which acetylates and therefore deactivates Cp23. Observation of CpR strains of Aeromonas
have shown an increase in MIC upon addition of more resistance factors24,25.
One of the most recently determined plasmid-mediated resistance genes belongs in the qnr
family23. The mechanism for FQ resistance as a result of Qnr proteins is not fully understood. One
hypothesis is that the pentatpeptide repeat regions that make up Qnr act to destabilize the complex
between Cp and DNA gyrase and allow DNA replication to occur23. The binding of Qnr proteins to DNA
gyrase before it can bind to DNA allows prevention of FQs from binding the complex at all23. The specific
gene qnrS2 has been found in both environmental samples and leech-associated A. hydrophila
infections26.
Plasmid-mediated resistance factors are important for the spread of antibiotic resistance.
Without the ability to transfer plasmids and plasmid-associated genes, qnr genes would not be so
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widespread. Several qnr genes have been found in association with transposons that would allow them
to be mobilized to different areas along the bacterial genome23. It has been hypothesized that qnrS
genes are close to and potentially derived from qnr-like determinants from Vibrio splendidus27. Because
Aeromonads are present in a variety of differing environments, further study could help determine if
they are an important reservoir for the horizontal transmission of qnr genes27. While the mechanism by
which qnr genes act may not be particularly well characterized at present, further research will provide
more information about their role in FQ resistance as a whole. Table 2 shows a list of qnrS2 isolates in
the scientific literature and the MIC values that the presence of the gene provides in Aeromonas, E. coli,
and Salmonella isolates.
A. hydrophila is one of the species implicated in Cp-resistant wound infections. One strain,
JG1471, was isolated from a leech shipped from Leeches USA, the only FDA-approved leech supplier in
the United States. JG1471 has an MIC of >32 µg/mL likely due to both chromosomal and plasmidmediated mechanisms. JG1471 has point mutations in both gyrA and parC, as well as a plasmidmediated resistance mechanism within a 6.8 kb plasmid, p1471. The plasmid p1471 contains a qnrS2
gene. It is likely that the chromosomal mutations give JG1471 an elevated Cp resistance, but that the
plasmid-associated qnrS2 gene boosts CpR to high levels (>32 µg/mL) above typical therapeutic
concentrations (1- 4 µg/mL Cp). Neither the mechanisms of qnrS2 nor the contribution to CpR is well
characterized at present. A common approach to the study of different genes and their effects is to
attach a gene of interest to a vector or other genetic tool that can allow expression of the gene in a new
strain to observe phenotypic differences.
One way to do this is to assemble a plasmid that ligates the gene of interest to a fragment that
allows for replication and selection of the newly assembled plasmid. A Gibson Assembly (GA) is a
procedure that is commonly used to accomplish this goal. It is a reaction that includes exonuclease, DNA
polymerase, and DNA ligase activity in one buffer, making it a simple and effective strategy to introduce
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new DNA sequences. Primers used for the GA must have an overhang where the two pieces of DNA can
overlap for the purpose of ligation. The exonuclease chews back the 5’ ends of the DNA fragments, the
fragments anneal where the primers overhang, DNA polymerase extends the 3’ ends, and DNA ligase
seals the nicks to leave a fully assembled plasmid containing the original fragments. Figure 1 shows a
diagram of how the GA works, while figure 2 shows the plasmids used for this research and the
experimental plan for the GA. The newly assembled plasmid should have factors such as novel antibiotic
resistance genes to provide selectivity, an origin of replication, and a multiple cloning site to allow future
options for gene exploration.
In order to explore the CpR coded by qnrS2, p1471 was isolated from JG1471 and ligated to a
pKAS46 fragment to allow for replication in E. coli and its selection yielding pEL1. The goal was to
combine p1471 with a pKAS46 fragment. The pKAS46 fragment contained an R6K origin of replication so
that the plasmid could use an E. coli system to replicate, a kanamycin (Km) resistance gene to confer
antibiotic resistance for selection of transformants, and a multiple cloning site (MCS) to allow for future
use of the assembled plasmid as a shuttle vector in experiments.
Upon transformation of the plasmid containing the resistance factors, pEL1, into E. coli and Cp
susceptible (CpS) Hm21 Aeromonas veronii, the MIC of the recipient strain should rise substantially due
to the presence of qnrS2 in the previously Cp susceptible (CpS) bacteria. If the pEL1 plasmid containing
qnrS2 is transformed into gyrA and parC mutants of Hm21RS (a CpS strain of A. veronii), the MIC of the
resultant cells should be higher than that of Hm21 A. veronii which does not contain any chromosomal
mutations to increase CpR in the QRDR. The increased MIC of the two mutants with and without the
presence of qnrS2 from pEL1 should provide a fuller picture of CpR in Aeromonas veronii as a whole.
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III. Methods
3.1 JG1471 isolation and genome sequencing
JG1471 was isolated from a Leeches USA shipment in February 2013 using a technique previously
described28. Briefly, leeches were anaesthetized in 70% alcohol and a dorsal incision was made to
withdraw intra-lumenal fluid (ILF) from the crop, a digestive compartment analogous to the stomach.
The ILF was cultured on media containing Cp at a clinically high concentration of 6 g/mL from which
JG1471 was isolated, subcultured, and frozen in glycerol stock for long-term storage. Genomic DNA was
extracted using MasterPure™ DNA and RNA Purification Kit and the NexteraXT libraries were prepared
for Illumina® MiSeq 2 x 250bp sequencing. Reads were combined and assembled using CLC Genomics
Workbench from Qiagen.
3.2 Strains, growth and storage conditions
All strains are kept in cryovials in a -80⁰C freezer. Aeromonas strains were incubated at 30⁰C and E. coli
strains were incubated at 37⁰C. Strains used from the collection are listed below in Table 1.

Table 1: Strains used for the GA and transformation. CpR=Resistant to >32 µg/mL Cp, KmR=resistant to
100 µg/mL kanamycin, CmR=resistant to 1µg/mL chloramphenicol
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3.3 Media preparation
LB broth was made by adding 10 g of BactoTM Tryptone (Becton, Dickinson and Co (BD) and Sparks, MD),
5 g of BactoTM Yeast Extract (BD and Sparks, MD), and 10 g of NaCl into 1 L of distilled water, and
autoclaved for 20 minutes at 121⁰C after which antibiotics were added when necessary. LB agar was
made by addition of 1.5% BactoTM agar (BD and Sparks, MD) before sterilization. Blood agar for E-testing
was prepared by the addition of 44 g of Columbia Blood Agar Base (Acumedia Inc. and Lansing, MI) to 1 L
of dH2O and sterilization at 121⁰C for 20 minutes. Mueller Hinton agar for E-testing was prepared by
addition of 38 g of Mueller HintonTM (BD and Sparks, MD) agar to 1 L of dH2O and sterilization.
3.4 Growth curves
Strain Hm21 and JG1471 from frozen stock were streaked for isolation on LB plates and LB with 4 µg/mL
Cp plates, respectively, and grown 16 hours at 30⁰C. Overnight cultures were made with 5 mL of LB and
4 µg/mL Cp and grown in 30⁰C shaker at 200 rpm for 16 hours. 50 µL of each culture was incubated in 5
mL of LB broth without antibiotics with shaking at 200 rpm at 30⁰C until the OD600 of the culture was
between 0.3 and 0.4. Once the subcultures reached that range, they were placed on ice. The volume of
the subculture required to start the growth curve with an OD of 0.005 and a 2 mL total volume was
calculated.
Absorbance measurements were taken in duplicate of the following bacterial cultures in respective
media: Hm21 + LB, Hm21 + 0.007 µg/mL Cp LB, Hm21 + 0.01 µg/mL Cp LB, Hm21 + 0.05 µg/mL Cp LB,
Hm21 + 1 µg/mL Cp LB, and Hm21 + 4 µg/mL Cp LB. JG1471 was grown and measured at the same Cp
concentrations listed for Hm21. 200 µL of each mix was added to a 48-well plate. A set of control wells
were measured for absorbance containing media but no bacterial culture. These wells were used to
measure background absorbance and this value was subtracted from the absorbance measurements of
each bacterial culture in media containing the respective Cp concentration. For example, if X absorbance
units were measured in LB with no Cp added, then X was subtracted from the average of triplicate
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measurements of bacterial culture + LB no Cp. The plate was measured using a Biotek ® Microplate
reader at 30⁰C over 24 hours and readings were taken every 10 minutes.
3.5 Plasmid isolation and purification
The strains containing plasmids p1471 and pKAS46 were streaked from frozen stocks for isolation on 4
µg/mL Cp LB plates and 100 µg/mL Km plates respectively. JG1471 was grown at 30⁰C for 16 hours. E.
coli + pKAS46 was grown at 37⁰C for 16 hours. Overnighters were then made with 10 mL LB and the
required antibiotic and incubated for 16 hours at 225 rpm. Plasmid purification was performed using the
Wizard® Plus SV Minipreps DNA Purification System (Promega, Madison, WI). To confirm isolation of the
plasmid, purified plasmids were run on an 0.8% SeaKem® LE Agarose gel (Lonza, Hopkinton, MA) for 40
minutes at 85V.
3.6 Gibson Assembly and Transformation into E. coli.
To ligate p1471 to a fragment of pKAS46, the first step of the GA was isolation of the plasmid as
described above. Then, the 6.8kb p1471 and 2 kb pKAS46 fragments were PCR amplified. The primers in
Table 3 were designed for a Phusion PCR reaction. All tubes included 2.5 µL of both the forward and
reverse primer, 25 µL of Phusion master mix, the amount of plasmid DNA required for a target of 5-10
ng in the reaction tube, and the required volume of PCR H2O for a total volume of 50 µL. For the p1471
reaction, the annealing temperature was 65⁰C. The following cycling conditions were applied: i) 98⁰C for
30 seconds, ii) 98⁰C for 10 seconds, 65⁰C for 30 seconds, and 72⁰C for 2 minutes, iii) Step ii repeats 30
times, iv) 72⁰C for 10 minutes, and v) held at 10⁰C indefinitely. In the pKAS46 reaction, the annealing
temperature of the primers is 62⁰C. The protocol requires that the reaction mix be heated at i) 98⁰C for
30 seconds, ii) 98⁰C for 10 seconds, 62⁰C for 30 seconds, and 72⁰C for 1 minutes and 10 seconds, iii)
repeat step ii 30 times, iv) 72⁰C for 10 minutes and v) 10⁰C indefinitely.
The template pKAS46 plasmid was prevented from being transformed in forthcoming steps by a
DpnI restriction digest. The pKAS46 plasmid was isolated and purified directly from bacterial cells, and is
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methylated. DpnI is a restriction enzyme that binds and digests at G-methylated A-T-C in both the
forward and reverse direction29. Since DpnI only digests methylated DNA, any remaining pKAS46
template was be digested but the amplified 1.9 kb fragment remained uncut as the PCR product was not
methylated29. 5µL of Cutsmart Buffer, 1 µL of DpnI enzyme, the volume required for 1 µg of pKAS46 and
the volume of PCR H2O required for a 50 µL total volume were combined in a PCR tube and placed at
37⁰C for 16 hours, 80⁰C for 20 minutes for enzyme inactivation, and then held at 10⁰C indefinitely.
Next, the GA was performed to ligate the insert and vector fragments. A 1:1 (p1471 to pKAS46)
GA ratio, a pUC19 positive control, and a negative control with neither p1471 or pKAS46 present were
used. The total volume in the GA tube was 10 µL. 5 µL was made up of the GA master mix. The amount
of p1471 should be 50 ng total. In order to have a 1:1 GA ratio, the concentration of pKAS46 DNA
required was 0.011 pmoles, and the total amount (ng) of pKAS46 required was 29 ng. The DNA was
added to the GA tube with the appropriate amount of dH2O for a total concentration of 10 µL. The
negative control contained 5 µL of GA master mix and 5 µL of dH2O. The three GA reaction tubes were
incubated for 30 minutes at 50⁰C and then placed on ice until used for transformation.
The three GA reactions were transformed into competent DH5α-λpir E. coli Hanahan cells30. The
transformation reactions contained the following: the 1:1 GA reaction, the GA reaction without DNA,
and pUC19 as a positive control. The Gibson assembly was diluted by adding 30 µL of distilled water to
the 10µL GA. Next, 2 µL of this dilution was added to a tube on ice and 50 µL of Hanahan competent
cells were added and mixed. 1 µL of pUC19 was added to the 50 µL of competent cells as a positive
control. The solutions were placed on ice for 30 minutes. They were heat-shocked in a 42⁰C water bath
for 1:15 minutes, removed and placed on ice for 3 minutes. Next, 950 µL of SOC media was added to
each tube. The samples were incubated with shaking (200 rpm) at 37⁰C for 30 minutes.
After the transformation, the cells were plated to select for growth. The 1:1 ratio and negative
control GA mixes were plated on LB and LB + 100 µg/mL Km for selection of transformants: a 10/90
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cell/SOC dilution on LB and LB + 100 µg/mL Km, and 100 µL directly spread on LB and LB + Km. The
leftover culture was centrifuged at 8000 rpm for 2 minutes, the supernatant was decanted, and the
culture was resuspended and spread on a Km plate. The positive controls were plated on LB+ 100 µg/mL
ampicillin (Amp) plates: 100 µL directly spread, a 10-fold dilution of 100 µL culture in 900 µL SOC (plating
100 µL total from the mix), and a centrifuged culture as mentioned above for the Amp plates. All plates
were incubated for 16 hours overnight at 37⁰C and growth was observed.
3.7 Confirmatory tests
Three colonies from the transformed pEL1 Km plate (from cells grown on the centrifuged GA 1:1
ratio of p1471 to pKAS46 Km plates) were streaked on 100 µg/mL Km plates. The plasmid pEL1
assembled with the Gibson assembly was then repurified from the E. coli cells and run on a gel using the
specifications mentioned in step 3.5 above. The next steps were diagnostic tests to confirm that the
plasmid isolated from the transformed cells was indeed pEL1. First, a diagnostic PCR was performed
using primers designed to detect qnrS2. Six plasmid purifications total were performed from the
subcultured isolated colonies, and they were tested with the qnrS2 primers. The sequences of the qnrS2
forward primer is GCAAGTTCATTGAACAGGGT, and the sequence of the qnrS2 reverse primer is
TCTAAACCGTCGAGTTCGGCG. A p1471 sample was used as the positive control for the PCR, with pKAS46
as the negative control. The reaction tubes include 12.5 µL of Taq polymerase, 0.25 µL of both the
forward and reverse primer, and 20-30 ng of template DNA (with PCR H2O to bring the tube volume to
25 µL total). The PCR tubes were put in the PCR machine and were heated to 94⁰C for 2 minutes then
94⁰C for 30 s, 50⁰C for 30 seconds, then 72⁰C for 30 seconds. The previous three steps repeated 30
times, and then the samples were heated to 72⁰C for 10 minutes and held at 10⁰C until removed from
the thermocycler. The PCR products were run for 45 minutes at 85 Volts on a 1.2% SeaKem® LE Agarose
gel to visualize the bands.
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The next diagnostic test consisted of PCR using the original primers that linearized the fragments for the
GA (listed in Table 3). If both the p1471 and pKAS46 fragments were amplified by the GA primers, the
identity of the isolated plasmid as pEL1 could be confirmed. The same six isolated plasmid samples used
for the qnrS2 diagnostic PCR mentioned above were used for the GA primer PCR. The GA PCR step
followed the same PCR instructions as were mentioned above in section 3.6. The PCR products were
then run on a 0.8% SeaKem® LE Agarose gel for 42 minutes at 85V.
3.8 Sanger Sequencing
pEL1 was sequenced from the left inverted repeat region of qnrS2 through both sites joining pKAS46 and
p1471. Based on the sequences of p1471 and pKAS46 previously determined through sequencing with
PacBio and Illumina, eight primers were designed for every 500-600 nucleotides. The annealing
temperature for the primers was between 55 and 65⁰C, 18-25 nucleotides long, with a 1 or 2 nucleotide
GC clamp on the 3’ end of the primer. The first primer began 50 nucleotides upstream of the inverted
repeat region of qnrS2 and the next primer was designed for 550 nucleotides downstream from there.
The primers used for sequencing pEL1 are shown in Table 4. Each primer’s sequencing container
contained 1.5 µL of 2.5x BigDye v1.1, 3 µL of 5x BigDye Buffer, 200 ng of plasmid template, and the
amount of dH2O for a total volume of 20 µL. The primer tubes were placed in a thermocycler and went
through these steps: i: an initial denature stage of 96⁰C for 2 minutes, a denature stage at 96⁰C for 20
seconds, an annealing phase of 10 seconds at 50⁰C, an extension phase at 60⁰C for 4 minutes. The three
previous steps were then repeated 32 times, and the tubes were held in the thermocycler at 12⁰C until
removed.
Next, 5 µL of EDTA solution at pH8 and 125 mM was added to each of the primer reactions. 70 µL of ice
cold 95% ethanol was added to the solutions and they were mixed by pipetting. The samples
precipitated overnight at -20⁰C. The samples were spun for 10 minutes at 4⁰C at max speed and the
supernatant was removed. 600 µL of 75% ice-cold ethanol was added to the tubes which were briefly
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vortexed and centrifuged at max speed for 10 minutes at 4⁰C again. The supernatant ethanol was
decanted. This ethanol step was repeated twice more. The excess ethanol was left to evaporate off the
tubes by leaving the lids of the MCF tubes open for 20-30 minutes. The samples were sequenced by the
DNA Biotech facility and the returned sequences were analyzed using SnapGene.
3.9 E-testing
E-testing was performed to quantify whether or not the addition of pEL1 provides E. coli cells with an
increased resistance to Cp. E-testing measures the minimum inhibitory concentration (MIC) of a certain
bacteria. MIC is the lowest concentration of the desired antimicrobial agent that is required to prevent
visible growth of a bacteria. First, strains are streaked for isolation on blood agar. The strains tested
were DH5α-λ pir E. coli without pEL1 and DH5α-λ pir E. coli with pEL1 present. For the Aeromonas Etesting, the strains tested were Hm21, Hm21+pEL1, Hm21RS, gyrA mutants of Hm21RS with and without
pEL1, and parC mutants of Hm21RS with and without pEL1 present. The quality control (E. coli ATCC
25922) was also streaked on blood agar. The plates were placed in the 35⁰C incubator for 18-20 hours. 4
mL of autoclaved 0.85% NaCl was pipetted aseptically into test tubes. All of the tested strains had a
single test tube. For each, isolated colonies were aseptically added from the blood agar plate until the
solution matched the turbidity of the 0.5 McFarland Standard. Autoclaved cotton swabs were placed in
the solution, allowed to sit for a minute, excess moisture was removed, and they streaked on Mueller
Hinton agar three times. Excess moisture was absorbed by letting the plate sit for 20 minutes. Forceps
were used to aseptically pick up the Etest® Cp strips (bioMérieux and Durham, NC), and place on the
agar with writing face up. The plates were incubated for 18-20 hours at 35⁰C and the Etest® strip was
read by observing the place on the strip where the apex of the zone of inhibition met the bacterial
growth.
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3.10 Transformation into CpS Aeromonas veronii
Preparation of competent Aeromonas cells31:
CpS A. veronii was inoculated in LB broth. It was incubated with shaking at 30⁰C overnight. 0.5 mL of the
overnight culture was added to 50 mL of SOB broth in a 250 mL Erlenmeyer flask. The bacteria grew at
30⁰C until the OD600 = 0.5. The cells were transferred to chilled centrifuge tubes. The culture was
centrifuged for 8 minutes at 6000 rpm at 4⁰C. The supernatant was poured off without disturbing the
culture. 1 mL of ice cold 10% glycerol was added and cells were resuspended by pipetting. 5 mL of ice
cold 10% glycerol was added to each tube and mixed gently. The centrifugation was run for 8 minutes,
6000 rpm at 4⁰C. The supernatant was decanted and the above steps were repeated from the 1 mL
resuspension three more times. After the wash steps, the supernatant was removed without pellet loss,
the remainder was transferred into MCF tubes, and centrifuged on a tabletop centrifuge for 8 minutes
at 60000 rpm at 4⁰C. The supernatant fluid was poured and the cells were resuspended in 150 µL of icecold 10% glycerol. 55 µL of the competent cells were used for each electroporation.
Electroporation of cells:
Electrocompetent Aeromonas cells were electroporated at 12kV/cm with 50 ng of purified pEL1 and
incubated in SOC medium for recovery at 35⁰C for one hour with gentle shaking as previously
described32.Transformation of Aeromonas with pMMB207 was conducted as a positive control. 10 ng
and 50 ng of pMMB207 DNA was added. 100 µL of the electroporated solution was plated on 1 µg/mL
chloramphenicol (Cm) plates, and 100 µL on LB agar. The rest of the solution was centrifuged for 2
minutes at 8000 rpm at room temperature, resuspended after all but 100 µL of the supernatant fluid
was poured off, and the cells were then resuspended and plated.
50 ng of pEL1 was used for the transformation, and 100 µL of the solution was plated on 100 µg/mL Km
plates, 100 µL on LB plates, and spun down and plated on 100 µg/mL Km plates as described for the
positive control.
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In order to explore qnrS2 and the p1471 plasmid further, 10, 50, and 100 ng of each p1471 and an IncU
plasmid were transformed into Hm21. The p1471 transformations were spun and plated on 1 µg/mL Cp
plates and the IncU transformations were spun and plated on 4 µg/mL Cp plates.
The two plasmids were each included in the experiment for different reasons. The IncU plasmid also
contains the qnrS2 gene, but is present only as a single-copy plasmid in the bacterial cell, where pEL1
and p1471 are high copy plasmids. Observing a difference in MIC between one copy and multiple copies
of qnrS2 could help provide more information on the gene and its mechanisms. To determine whether
the native plasmid could be transformed using the same methods, p1471 was included in the
transformation procedure and it was observed to see if there would be any phenotypic differences
between the p1471 and pEL1.
The procedure for competent Aeromonas cells and electroporation was repeated using gyrA-mutant
Hm21RS and parC-mutant Hm21RS to transform pEL1 into the two strains. Both were taken from frozen
stocks and streaked on 100 µg/mL streptomycin (Sm) plates. Colonies were inoculated from
streptomycin plate into 5 mL LB broth containing 100 µg/mL Sm and the cells were made competent
using the protocol above. When the transformed media was plated, the 100 µL direct volume to the Km
plates was not included in order to make sure there were enough transformed colonies in the plate that
included the results from the spun-down centrifuge step.
No plasmid was transformed in the negative controls, and 100 µL of the solution was plated on
100µg/mL Km plates, 1 µg/mL Cm plates, LB plates, and spun down and plated on 100 µg/mL Km agar.
The plates were placed at 30⁰C for 16-18 hours and results were recorded. The transformed colonies
were taken from the Km plates and streaked onto new Km plates for isolation, future overnight cultures,
creation of frozen stock, and isolation of plasmid using the protocol in 3.5. Plasmid identity was then
confirmed with the steps in 3.7.
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3.11 Oxidase testing
Oxidase testing was performed to support that the strains with pEL1 transformed were oxidase positive.
Colonies were scraped on a sterile Kim wipe that had been saturated with the oxidase test solution
(0.048 g of N’,N’,N’,N’-Tetramethyl-p-phenylenediamine dihydrochloride in 8 mL of nanopure water). A
positive oxidase test result was the appearance of a blue color upon addition of the colonies to the
saturated Kim wipe.
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IV. Results
4.1 Growth curve
It may be hypothesized that the increased energy needed to replicate p1471 as a high copy plasmid
would lead to some defect in the growth rate in LB when compared to Hm21 in the absence of
antibiotics. The growth rates of JG1471 and CpS control A. veronii strain Hm21 during the exponential
phase were determined in varying levels of Cp (Figure 3). In LB without Cp, Hm21 had a growth rate of
0.046 hr-1 while JG1471 had a slower growth rate of 0.007 hr-1. Though the growth rate with just LB was
higher for Hm21, the growth rate of JG1471 in the presence of Cp was consistently higher than that of
Hm21, as can be seen in Table 5. At 0.05, 1, and 4 µg/ml Cp, Hm21 had a growth rate of zero. While the
growth rate of JG1471 in LB was lower than that of Hm21 in LB, the growth yield of JG1471 was larger in
the stationary phase, with a higher optical density based on cell growth. JG1471 had the highest growth
yield when grown in the presence of LB + 4 µg/mL Cp. The ability of JG1471 to grow at 4 µg/mL Cp is a
result of Cp resistance mechanisms.
4.2 Bioinformatic Analysis of p1471
The CpR of JG1471 is likely a result of the mutations in gyrA and parC, as well as the presence of qnrS2 in
p1471. The CpR plasmid p1471 contains qnrS2, which may play a role in its high MIC, but qnrS2 is not the
only gene present on the plasmid. It also contains a gene coding for the NspV endonuclease type II
restriction enzyme that could be involved in ensuring the maintenance of the plasmid. Downstream
from this is an nspV modification methylase gene to protect its own DNA against the cleavage action of
the NspV restriction enzyme33. This is a common mechanism used by bacteria and archaea to disrupt the
DNA of potential pathogens while still protecting the host DNA but it has also been proposed as a
mechanism to ensure plasmid stability33. p1471 also contains a repB gene, which codes for a plasmid
replication protein that may help regulate replication of the plasmid34. Another gene on p1471 is an
addiction module antitoxin. While toxin/antitoxin systems have not been well characterized, it has been
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hypothesized to be similar to the nspV endonuclease and methylase system, with toxic actions
counteracted by the antitoxin encoded on its own plasmid35. The combination of the toxin/antitoxin and
nspV restriction enzyme system could provide JG1471 with an increased protection against foreign
microbes or pathogens. The important genetic marker for CpR on the plasmid is the aforementioned
qnrS2. In order to study the resistance that the presence of qnrS2 provides, the p1471 plasmid was
ligated to the pKAS46 1.99 kb fragment using the GA and transformed into CpS bacteria.
4.3 Plasmid isolation and purification
The 1.99kb pKAS46 fragment was chosen for several reasons. An origin of replication was included (R6K)
to allow for replication of the plasmid after transformation into E. coli. The addition of the R6K origin of
replication allowed for this replication in DH5α-λpir cells but shout not change replication or the copy
number in Aeromonas as plasmids with the R6K ori are suicide vectors in Aeromonas36 . The Kmresistance marker present in the pKAS46 fragment allowed for selection of transformed colonies after
the GA and transformation. This extra selective marker was helpful because the Cp resistance provided
by the presence of qnrS2 in the plasmid was not quantified, so 100 µg/mL Km plates were used to select
for successfully transformed cells. The multiple cloning site in the pKAS46 fragment allows for future use
of the plasmid as a shuttle vector in experiments. Transformation into Aeromonas has been problematic
in the past, so a well-characterized shuttle vector such as pEL1 that transformed successfully would be a
valuable tool for future use.
In order to isolate the p1471 and pKAS46 plasmids for the GA protocol, a Wizard® Plus SV Minipreps
DNA Purification System was used. In Figure 4, a 0.8% SeaKem® LE Agarose gel shows the successful
isolation of the two plasmids. p1471 shows a band at 6.8 kb and pKAS46 shows a band at 5.9 kb. After
purification of the two plasmids, the GA was performed to ligated the p1471 and pKAS46 fragments.
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4.4 Gibson Assembly and Transformation
In order to continue with the GA, p1471 and the 1.99kb fragment of pKAS46 were amplified by
PCR for a linear product. In Figure 5, a 0.8% SeaKem® LE Agarose gel suggests that the PCR amplification
was successful; both p1471 and the pKAS46 fragment show the expected band size. Figure 2 shows a
diagram of the fragments and ligated construct of pEL1.
After amplification of p1471 and the fragment from pKAS46, a DpnI digest was performed to
digest the methylated template DNA from the pKAS46 PCR tube. In previous experiments without this
DpnI step, pKAS46, rather than pEL1, was re-isolated at the end of the transformation procedure
because the template DNA from the PCR out-competed the assembled plasmid. Figure 6 shows the
difference between a confirmatory PCR with qnrS2 with and without the addition of the DpnI digest to
the protocol. In A, no qnrS2 was detected from the transformed plasmid because pKAS46 was repurified rather than p1471. In B, a DpnI digest was performed before the GA protocol, the pKAS46
template DNA was not transformed, and the pEL1 plasmid annealed properly.
After the fragments annealed, the newly assembled pEL1 plasmid was transformed into Hanahan
cells. The marker for a successful transformation was the presence of colony growth on the Km plates
from the GA transformants. The 1:1 p1471 to pKAS46 GA ratio provided 6 distinct colonies on the 100
µg/mL Km plate from the centrifuged and concentrated cells. Of these six distinct colonies, three were
streaked on Km plates for isolation, and confirmatory assays were performed to make sure that the
transformation products did contain pEL1.
4.5 pEL1 confirmatory assays
In order to confirm that the transformed colonies from the Km plate actually received their Km
resistance from pEL1 rather than pKAS46, several confirmatory assays were performed. First was the
PCR reaction with qnrS2 primers mentioned in part 4.2. The gene qnrS2 was part of the pEL1 assembled
construct due to the addition of the p1471 fragment to the assembly. Because the qnrS2 primers did
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show amplification of the qnrS2 gene from the plasmid in part B of figure 5, there was evidence that
p1471 was present in the final construct.
The next confirmatory assay was a PCR using the original primers designed to linearize the
fragments for the GA. If the fragments assembled correctly to make pEL1, both p1471 and the 1.99kb
pKAS46 fragment should have been amplified when pEL1 was tested. The confirmatory PCR with the GA
primers was a success. Samples B-F in Figure 7 show a band near 6.8kb, exactly where the p1471 linear
fragment is expected to be. Sample A seems to have some form of truncated version of the fragment, so
this particular pair of the E. coli and plasmid were excluded from future experiments. Samples A-F all
show the expected 2kb band of the amplified pKAS46 fragment. The diagnostic assays confirmed the
identity of the transformed plasmid to be pEL1 and frozen stocks were made of E. coli with the plasmid
for use in future experiments.
4.6 Sanger Sequencing
After confirmation of successful p1471 and pKAS46 assembly, sequencing confirmed that no
mutations or ligation mistakes had occurred during the GA process. If a mutation had occurred in qnrS2
or part of the pKAS46 fragment, future tests could be impacted. Eight primers were designed to amplify
the assembled region. Because qnrS2 is the gene of interest in the p1471 plasmid, primers were
designed to begin at the left of the inverted repeat region of the gene and continue through qnrS2, its
right inverted repeat region, and pass all the way through the pKAS46 fragment. The eighth primer did
not bind or amplify the DNA, but primers 1-7 did sequence the desired region, as seen in Figure 8. The
seven primers sequenced the pEL1 area of interest and showed definitively that there were no
mutations in the sequence of the plasmid as compared to the original components. The plasmid pEL1
was successfully assembled and transformed into E. coli without mutations.
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4.7 E testing of E. coli + pEL1
The presence of the pEL1 plasmid allowed for a test to determine the phenotypic changes
associated with the presence of the plasmid in E. coli. In order to determine what level of CpR was
conferred to the susceptible strain upon addition of the pEL1 plasmid, E-testing was performed to
determine the MIC of Cp for the bacteria. ATCC25922 E. coli was used as a quality control for the Etesting and showed an MIC within the expected bounds.
DH5α-λ pir E. coli showed a marked increase in MIC upon addition of pEL1 (Table 6). The MIC
increased from 0.032 µg/mL without plasmid to 0.25 µg/mL when pEL1 was present in the bacteria.
Because this E. coli strain does not have any of the chromosomal mutations that lead to CpR, the change
in resistance of this strain is likely due to pEL1 and the presence of the gene qnrS2.
4.8 Transformation of pEL1 into A. veronii
In order to study the effect of the presence of qnrS2 in CpS Aeromonas, pEL1 was transformed into
A. veronii. After transformation of five reactions containing 50 ng of pEL1 added to 55 µL competent A.
veronii, a total of 13 isolated colonies grew on the spun-down plates across the five reactants. Five of
the colonies were streaked for isolation, inoculated in overnighter cultures, and saved as frozen stocks.
The positive controls showed growth of many colonies containing pMMB207 growing on 1 µg/mL Cm
plates, and the negative control showed a lack of growth on all plates except LB. p1471 and an IncU
plasmid containing qnrS2 were also transformed in Hm21 but neither yielded any transformants on the
selective Cp media. pEL1 was purified from frozen stocks #1 and #2 of Hm21 pEL1. From there, qnrS2
and GA primers were used to confirm the identity of the transformed plasmid as pEL1. The presence of
PCR products using the qnrS2 and GA primers (Fig. 9), confirms that pEL1 was present in Hm21 + pEL1.
pEL1 was transformed into gyrA and parC mutants of Hm21RS A. veronii. gyrA and parC Hm21RS
mutants are both hypothesized to have an increased CpR due to the genomic mutation, so
transformation of pEL1 to each allowed further exploration of the MIC conferred by the different
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resistance factors. There was a lawn of growth on the 100 µg/mL Km plates (transformed with 10, 50,
and 100 ng of pEL1). Fig. 10 shows the presence of qnrS2 in all but two of the Hm21RS gyrA and Hm21RS
parC strains after colony PCR of the transformed cells. Oxidase tests were performed on all transformed
colonies to support that Aeromonas was the recipient bacteria. The oxidase tests were positive as
expected for Aeromonas. The next step was to observe the MIC change in Aeromonas as a result of
pEL1.
4.8 E-Test of Aeromonas + pEL1
Transformation of pEL1 into strains of CpS A. veronii was hypothesized to lead to an increased
MIC for each strain as a result of the presence of qnrS2. After transformation of the qnrS2 containing
pEL1 plasmid into the CpS A. veronii bacteria in the first trial, the MIC increased to 6 µg/mL from its
starting point of 0.002 µg/mL. The addition of the pEL1 plasmid led to a dramatic increase in the MIC
and changed a CpS strain of Aeromonas to a CpR one. Table 7 shows the MIC results for the 1st and 2nd Etest trials.
After the second trial of E-testing, the MIC results of Hm21 A. veronii + pEL1 showed a different
MIC value; instead of the 6 µg/mL MIC determined in trial 1, the MIC was 0.032 µg/mL. While there is a
large difference between the MIC values from the two trials, both values support that addition of qnrS2
to a CpS strain of Aeromonas increases the MIC dramatically. The gyrA Hm21RS mutant showed a
phenotype MIC of 0.094 µg/mL before transformation of the plasmid due to its genomic mutation, and
0.125 µg/mL after addition of pEL1. The parC Hm21RS mutant did not contain inherent resistance as a
result of the genomic mutation, but increased from 0.003 µg/mL to 0.032 µg/mL after transformation of
pEL1, just as the second Hm21 + pEL1 trial did.
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V. Discussion
Bacteria with elevated resistance to Cp are increasingly being isolated in hospitals, and a greater
understanding of the factors which contribute to Cp resistance and how they are acquired is needed to
combat this growing problem. Aeromonas species can be found in water sources such as hospital
wastewater, drinking water in cities, and natural aquatic environments in addition to the leech gut37. It
has been suggested that horizontal transfer in such settings plays a role in the acquisition of antibiotic
resistance determinants later found in clinical and environmental isolates37. This factor combined with
the widespread overuse of antibiotics leads to a buildup of Cp in the environment and selection of
resistant bacteria37,38. Selection for resistance factors due to the presence of low-level Cp in the
environment may be the mechanism by which leech symbionts acquire resistance factors. JG1471 may
have adapted to grow slightly better in the presence of Cp if the bactericidal agent is found, as has been
suggested, in many water and waste sources3>. The high Cp resistance found in JG1471 is likely a result
of gyrA and parC mutations in the genome and the qnrS2 gene present on the p1471 plasmid.
The gene qnrS2 is a resistance factor that has not been well characterized but is observed in
Aeromonas strains isolated from the environment and clinical sources24,40. This resistance gene has been
discovered on IncU and IncQ-like plasmids that take part in conjugative transfer and is a likely
mechanism by which qnrS2 and other qnr genes have disseminated into environmental isolates24,41. In
order to study the qnrS2 gene present in p1471, p1471 was ligated the 2kb fragment of pKAS46 to form
the pEL1 plasmid. The addition of the R6K origin of replication allowed the pEL1 plasmid to replicate in
DH5α-λpir E. coli but did not affect the copy number of pEL1 in Aeromonas because of the role of
pKAS46 as a suicide vector in Aeromonas36.
When qnrS2 was transformed into the CpS DH5α-λ pir E. coli cells, there was an MIC increase
from 0.032 µg/mL to 0.25 µg/mL. These results were consistent with those in previous literature about
qnrS2 addition to E. coli (Table 2). When plasmids containing qnrS2 were conjugated from Aeromonas
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species into various strains of E. coli in other studies, the MIC values were similar. One E. coli
transconjugant experienced a change from 0.015 µg/mL to 0.25 µg/mL upon addition of the gene 42. Two
separate qnrS2 isolated plasmids conferred an increase from <0.01 µg/mL to 0.25 µg/mL in both E. coli
TOP10 transconjugants24. One qnrS2 plasmid found in a clinical sample changed the MIC of E. coli from
0.023 µg/mL to 0.5 µg/mL, while another environmental qnrS2 plasmid changed the E. coli MIC from
<0.02 µg/mL to 0.15 µg/mL4>,43. While not all the MIC values for E. coli + qnrS2 are exactly the same, all
are low when compared to the 4 µg/mL clinical cut off for resistance. This increase in MIC in E. coli
continues to support the hypothesis that the presence of qnrS2 increases CpR, but it does not suggest if
MIC values are comparable when pEL1 is present in a CpS Aeromonas strain
Because the R6K origin of replication does not allow for replication in Aeromonas strains, the
origin of replication coded by the p1471 plasmid is used, which suggests that the copy number of pEL1
in the A. veronii recipient strain is comparable to the copy number from its original host, JG1471. The
original plasmid p1471 is a very high copy plasmid in A. hydrophila. The successful assembly and
transformation of pEL1 into E. coli and A. veronii provided an opportunity to evaluate the level of Cp
resistance conferred by pEL1 to both bacteria, as determined by E-testing. While addition of pEL1 to E.
coli (DH5α λ-pir) caused a ~8 fold increase in the observed MIC (from 0.032 µg/mL to 0.25 µg/mL), the
transformation of pEL1 into a CpS A. veronii led to an unexpected 10.5 to 3,000 fold MIC increase (0.002
µg/mL to 0.032 and 6 µg/mL in two independent experiments). Although not determined, it is likely that
qnrS2 is expressed in the recipient strains and is responsible for the observed MIC increase, though the
exact mechanism of qnrS2 is unknown. High copy levels of qnrS2 present in the cell may lead to a higher
level of CpR. While qnrS2 gene conjugation in previous studies has shown an MIC increase in E. coli, as
seen in Table 2, the resultant bacteria were still CpS with MIC values closer to 0.25 or 1. In cases where
the qnrS2 gene was present in the bacteria without other resistance factors, both Aeromonas and
Salmonella strains isolated from the environment and clinical samples showed a CpS phenotype4>,44. The
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addition of the pEL1 plasmid to Hm21 A. veronii led to a dramatic increase in the MIC and changed a CpS
strain of Aeromonas to a CpR one. Further study of how this plasmid increases the MIC of Cp in
Aeromonas strains when genomic substitutions in the QRDR are already present will help determine
how various combinations of these genetic determinants alter overall CpR.
The addition of the qnrS2 gene to gyrA and parC Hm21RS mutants also showed an increase in
MIC in Table 7 after E-testing. The gyrA mutant had an MIC of 0.94 µg/mL before transformation, likely
due solely to the mutation in the QRDR of gyrA. After transformation with pEL1, this MIC increased to
0.125 µg/mL. This showed an MIC increase that was likely based on the combination of the gyrA
genomic mutation in the QRDR and the plasmid-mediated qnrS2 CpR gene. The parC Hm21RS mutant
itself did not show any inherent CpR despite its genomic mutation, with an MIC of 0.003 µg/mL. But after
addition of pEL1 and qnrS2, the MIC of the parC Hm21RS mutant increased to 0.032 µg/mL. A second
trial of Hm21 + pEL1 led to an MIC increase of 0.003 µg/mL to 0.032 µg/mL. This ~10.5-fold increase in
MIC is in stark contrast to the 3,000-fold MIC increase shown in the first E-test of CpS Hm21 + pEL1.
Future research will explore the reason for the difference in MIC measured from the same transformed
bacteria. It is possible that the copy number of the pEL1 plasmid is subject to the stage of cell growth;
determination of plasmid copy number in the literature has been shown to be variable based on the
stage of growth of some bacteria, whether they are in lag, exponential growth, or the stationary
period45. It is possible that there was a lower copy number of pEL1 due to a change in bacterial growth
that led to a decrease in MIC after the second trial of E-testing. The next steps will be E-testing of the
Hm21 + pEL1 bacteria after being grown to different growth points to explore whether this results in a
change in MIC that could account for the observed discrepancy. While the MIC values are different
between the two trials of CpS Hm21 pEL1, the MIC of every strain tested was increased after
transformation with pEL1. It is likely that the addition of qnrS2 was responsible for the increase in MIC
observed in the transformed strains.
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Future research will focus on further understanding the role qnrS2 has in Cp resistance. Because
pEL1 is a high copy plasmid in A. veronii, it is likely that increased copies of qnrS2 lead to the 6 µg/mL
MIC observed. In order to study this hypothesis, a conjugative transfer will take place with an IncU
plasmid, previously purified from a CpR Aeromonas leech symbiont, that contains a copy of the qnrS2
gene. IncU is a single-copy plasmid, which means that qnrS2 would only be present as a single copy. It is
expected that with this single copy of qnrS2 in the susceptible strain, the MIC will be lower than that
determined after transformation of pEL1 with its likely high copy number. Further research will be
performed to determine the specific copy number of the plasmid in each host strain so that exact
comparisons can be made. Efforts will also continue to transform the native plasmid, p1471, into the CpS
A. veronii strain to determine whether the addition of the 2kb pKAS46 fragment to the p1471 plasmid
caused any phenotypic differences in MIC.
One area of future study will be determining if growth defects are caused by the presence of
various CpR determinants such as genomic mutations in the QRDR or plasmid-mediated factors like
qnrS2. This will be accomplished by performing growth curves of A. veronii strains with and without the
resistance factors to compare rates. The growth rate of CpR JG1471 was lower than that of CpS Hm21 in
LB without Cp (table 5), but JG1471 with and without Cp showed a higher growth yield. One hypothesis
is that the strains with the highest CpR will have a decreased growth rate like JG1471 because the cell is
expending so much energy on producing compounds to resist Cp-mediated cell death. While the
research of levels of CpR and their effects are clinically relevant, they are not the only applications of
JG1471 and qnrS2.
The MCS of pEL1 provides the option of its use as a shuttle vector for future studies in
Aeromonas. A shuttle vector is a valuable biological tool that allows for addition of a gene of interest or
DNA recombination46. Shuttle vectors are widely used in the biological sciences, with uses including
genetic engineering and gene cloning in yeast and bacteria47. These tools are often used to express a
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protein of interest in a bacteria or host that was not native to it and observe the phenotypic changes47.
Since pEL1 is transformable into A. veronii, this plasmid may be used to express other genes or factors of
interest using the MCS. There is some evidence that, after a gene deletion, complementation via
plasmid may produce unstable results or false negatives due to plasmid instability or the copy number
of the plasmid in the cell48. The potentially variable copy number of pEL1 due to the presence of p1471
in Aeromonas cells could be a factor in effectiveness of this plasmid as a shuttle vector.
If the shuttle vector is successful, however, the MCS could be used to insert other resistance
factors into the plasmid and study their effects. Addition of a qepA or oqxAB gene that codes for an
efflux pump and the subsequent change in resistance could provide an interesting future direction,
especially if the qnrS2 gene is removed from the plasmid to study the effect of the efflux pumps without
outside resistance factors. New CpR factors are continually being discovered due to increasing CpR in
Aeromonas and other bacteria, and this field of study will likely continue to expand and increase in
importance as bacterial antibiotic resistance becomes more prevalent.
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VI. Conclusion
The antibiotic resistance plasmid pEL1 was assembled correctly using a Gibson Assembly; confirmatory
PCRs and Sanger sequencing confirmed a successful assembly and a complete sequence match to what
was expected. This pEL1 plasmid could prove a valuable tool as an Aeromonas shuttle vector in future
research. The presence of the gene qnrS2 is an important resistance factor of pEL1. The presence of
qnrS2 provides a significant increase in MIC in susceptible strains. In E. coli, the presence of the gene
brought the MIC from 0.016 µg/mL to 0.25 µg/mL. In CpS A. veronii, the MIC changed from 0.002 µg/mL
in the susceptible strain to 6 µg/mL in trial 1 and 0.003 µg/mL to 0.032 µg/mL upon addition of the
plasmid in trial 2. qnrS2 can also combine with genomic resistance factors to increase MIC. The gyrA
Hm21RS mutant had an inherent MIC of 0.094 µg/mL due to the mutation in the QRDR and increased to
0.125 µg/mL in the presence of qnrS2. The MIC differences shown in trial 1 and trial 2 may be a result of
the copy number of pEL1 varying depending on cell growth stages and leading to a range of CpR
phenotypes due to the different number of copies of the qnrS2 gene.
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VII. Figures
Table 2: Examples of qnrS2 and its effect on the MIC of different bacteria in the literature

Reference
Mobilizable IncQ-Related Plasmid Carrying a New Quinolone Resistance
Gene, qnrS2, Isolated from the Bacterial Community of a Wastewater
Treatment Plant

Year

Gene
present

2006 qnrS2

qnrS2
Plasmid-mediated QnrS2 determinant from a clinical Aeromonas veronii
isolate

2008 qnrS2

qnrs2
Unexpected occurrence of plasmid-mediated quinolone resistance
determinants in environmental Aeromonas spp.

2008 qnrS2

qnrS2

qnrS2

qnrS2
Plasmid-mediated quinolone resistance in
Aeromonas allosaccharophila recovered from a Swiss lake

2008 qnrS2

qnrS2
Coprevalence of plasmid-mediated quinolone resistance determinants
QepA, Qnr, and AAC(60 )-Ib-cr among 16S rRNA methylase RmtBproducing Escherichia coli isolates from pigs

Plasmid-mediated QnrS2 determinant in an Aeromonas caviae isolate
recovered from a patient with diarrhoea

Ornamental fish as a source of plasmid-mediated quinolone resistance
genes and antibiotic resistance plasmids

Not specified N/A
from <0.02
µg/mL to 0.15
µg/mL
N/A
8 µg/mL
from 0.023
µg/mL to 0.5
µg/mL

gyrA and parC

none
one amino acid substitution
in Ser83Ile in GyrA

4 µg/mL
from <0.01
µg/mL to 0.25
µg/mL
N/A
two amino acid substitutions
in Ser83Ile in GyrA and
>32 µg/mL
Ser80Ile in ParC
from <0.01
µg/mL to 0.25
µg/mL
N/A

0.12 µg/mL
none in QRDR
from <0.01
µg/mL to 0.25
µg/mL
N/A

Bacteria

Plasmid
pGNB2
Activated sludge (IncQ
bacteria
type)
pGNB2
(IncQ
E. coli KAM3
type)

Type of Isolate

A. veronii

pA272

Clinical

A. punctata

pA272
p37 (IncU
type)

Environmental

E. coli TOP10
transconjugant

p37 (IncU
type)

A. media

p32 (IncU
type)

E. coli TOP10
transconjugant

p32 (IncU
type)

E. coli
transconjugant

A.
p34 (IncU
allosaccharophila type)
E. coli TOP10
transconjugant

Salmonella
enteritidis

p34 (IncU
type)
plasmid
type not
specified
plasmid
type not
specified
plasmid
type not
specified
plasmid
type not
specified
plasmid
type not
specified
plasmid
type not
specified
plasmid
type not
specified
plasmid
type not
specified
plasmid
type not
specified
plasmid
type not
specified
plasmid
type not
specified
plasmid
type not
specified
plasmid
type not
specified
plasmid
type not
specified

Escherichia coli
transconjugant

IncU

rmtB-positive E.
coli
rmtB- positive E.
coli
transconjugant

0.5-1 µg/mL (2
samples)
none

Salmonella
Braenderup

qnrS2

0.5 µg/mL

none

Salmonella
Agona

qnrS2

0.5 µg/mL

none

Salmonella
Alachua

not specified

not specified

A. caviae

2009 qnrS2

2010 qnrS2

qnrS2
First description of the qnrS-like (qnrS5) gene and analysis of quinolone
resistance-determining regions in motile Aeromonas spp. from diseased
fish and water.

Chromosomal mutations

not specified N/A
from 0.015
µg/mL to 0.06
µg/mL
N/A

2008 qnrS2

qnrS2
Plasmid-Mediated Quinolone Resistance in Salmonella Isolated from
Patients with Overseas Travelers' Diarrhea in Japan

Increase in
MIC of Cp

0.75 µg/mL to
1.5 µg/mL
not specified

transconjugant

16 µg/mL

amino acid substitutions in
gyrA and parC

A. sobria

qnrS2

256 µg/mL

amino acid substitutions in
gyrA and parC

A. hydrophila

qnrS2

4 µg/mL

amino acid substitutions in
gyrA and parC

A. hydrophila

qnrS2

0.012 µg/mL

none

A. hydrophila

2014 qnrS2

8 µg/mL

unknown

A. hydrophila

qnrS2

4 µg/mL

unknown

A. hyrdophila

2012 qnrS2

Prevalence and characterisation of quinolone resistance mechanisms in
Salmonella spp.

2014 qnrS2

Quinolone resistant Aeromonas spp. as carriers and potential tracers of
acquired antibiotic resistance in hospital and municipal wastewater

2016 qnrS2

2 µg/mL
gyrA substitution
from 0.015
µg/mL to 0.25
µg/mL
No

Environmental

Environmental

Environmental

Veterinary

Clinical

Clinical

Diseased Fish

Diseased Fish

Diseased Fish

Diseased Fish

Koi Carp

Koi Carp
Animals, food,
and feed
Aeromonas
donor from
clinical setting

34

Figure 1: After primers are designed to overlap each fragment, the GA assembles the DNA. The 5’ ends
are chewed back by exonuclease, DNA polymerase extends the 3’ ends of the DNA after it has annealed,
and DNA ligase seals the nicks in DNA for a fully assembled plasmid49.
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A

B

C

Plasmid
p1471
p1471
pKAS46
pKAS46

Figure 2: The addition of 1.9
kb pKAS46 fragment
containing Km resistance
gene, R6K origin of
replication, and Multiple
Cloning Sites to p1471 using
the Gibson Assembly. A is
the p1471 plasmid. B is the
pKAS46 plasmid with red to
highlight the desired
fragment. C is the pEL1
assembled plasmid

Direction
Forward
Reverse
Forward
Reverse

Primer sequence
CCCAAGAGGAACAAATCGCTC
GGGGCAACCATAAAAACAGC
GCTGTTTTTATGGTTGCCCCgagcgtgacaatcacgaaac
AGCGATTTGTTCCTCTTGGGggtgttgctgactcataccag

Table 3: The primers designed using SnapGene to linearize the p1471 plasmid and the 2kb fragment of
pKAS46 and allow ligation during the Gibson Assembly

36

Primer Name
E1
E2
E3
E4
E5
E6
E7
E8

5'-3' orientation
CGTTTCGACACACAAGGCAG
TGGCAGCGATCAGAGTACAC
TTCCAACAATGCCAGCTTGC
AAACGTGTTTGAATGGGGCC
TCACGTACTAAGCTCTCATGTTTG
GTAATACAAGGGGTGTTATGAGCC
GCTTTTGCCATTCTCACCGG
CCCCAAGAGGAACAAATCGC

Annealed correctly?
Yes
Yes
Yes
Yes
Yes
Yes
Yes
No sequence

Table 4: The primers designed using SnapGene to sequence the area of interest in the pEL1 plasmid.
Primer E1 begins on the left of the inverted repeat region of qnrS2, and Primer 7 ends just after the
ligation site between pKAS46 and pEL1. The entire qnrS2 gene and pKAS46 fragment are sequenced.

Figure 3: Increased Cp leads to growth defect in Hm21, which is CpS . The presence of p1471 may lead to
a growth defect in LB, but provides a growth advantage in JG1471 when 4 µg/mL Cp is present in the LB
growth medium.
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LB+0.007 LB + 0.01 LB + 0.05 LB + 1
µg/mL
µg/mL
µg/mL
µg/mL
Cp
Cp
Cp
Cp

LB
Hm21 growth rate
(hr^-1)
JG1471 growth rate
(hr^-1)

LB + 4
µg/mL
Cp

0.046

0.027

0.034

0

0

0

0.007

0.04

0.044

0.042

0.032

0.03

Table 5: The specific growth rates for the Hm21 and JG1471 growth curves in LB + Cp

Figure 4: The 6.8kb p1471 and 5.9kb pKAS46 were both successfully isolated by using the Promega
Wizard miniprep kit.

Figure 5: The linear fragments amplified by Gibson Assembly primers for p1471 and pKAS46: p1471 is
a linear 6.8 kb, while pKAS46 primers solely amplified a 1.99kb fragment containing the R6K, KmR,
and MCS.
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Figure 6: The importance of the DpnI digest to prevent transformation of template plasmids such as
pKAS46. A shows the ultimate results of the transformation and plasmid purification if the DpnI digest
does not cut up the methylated DNA. B shows the confirmatory testing of qnrS2 PCR when the DpnI
digest is performed to digest pKAS46. Without the DpnI digest, pEL1 was not successfully transformed
because it was out-competed by the template pKAS46 used for PCR.

A

B

Figure 7: In A, the transformed and purified plasmid is tested using PCR using the original p1471 GA
primers. Isolated plasmids B-F all show the expected 6.8kb band for p1471In B, the plasmids are tested
using PCR using the pKAS46 GA primers to produce a 2kb fragment. Samples A-F all show a band at the
2kb length where the samples should be. In samples B-F, both fragments were observed after
purification form the transformed plasmids.
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Figure 8: Seven primers designed to amplify the area of ligation of the pEL1 plasmid showed successful
assembly of the plasmids. No point mutations or changes of any kind were found in the sequence.

Strain
E. coli
E. coli
E. coli

plasmid
none
pEL1
pEL1

MIC (µg/mL)
0.032
0.25
0.25

Table 6: MIC results from transformation of pEL1 into DH5αλpir E. coli cells.
A

Figure 9: A shows the results of a PCR using qnrS2
primers. It confirms that the isolated plasmids contain
qnrS2. Figure B shows the results of a PCR using the
GA primers, with the p1471 fragment above and the
pKAS46 fragment below. pEL1 #2A was used in further
transformation into the mutant strains of A. veronii.
B
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Figure 10: qnrS2 colony PCR of gyrA and parC Hm21RS mutants after transformation of the pEL1
plasmid. Moving forward, gyrA mutant #1 and #2 were used, as were parC mutants #1 and #2 because
they both had confirmed pEL1 presence using qnrS2 PCR.

Strain
Hm21
Hm21
Hm21RS
gyrA mutant
Hm21RS
gyrA mutant
Hm21RS
parC mutant
Hm21RS
parC mutant
Hm21RS

MIC (µg/mL)
Plasmid Trial 1
Trial 2
none
0.002
0.003
pEL1
6
0.032
none
N/A
0.003
none

N/A

0.094

pEL1

N/A

0.125

none

N/A

0.003

pEL1

N/A

0.032

Table 7: MIC values determined with and without the presence of pEL1 in recipient Aeromonas strains
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